Publication Date: 15 Dec 2011
Type: Review
Journal: Clinical Medicine Reviews in Therapeutics
Citation: Clinical Medicine Reviews in Therapeutics 2012:4 1-12
doi: 10.4137/CMRT.S3236
Glaucoma is the name given to a group of diseases characterized by incurable, progressive, multifactorial optic neuropathy. It is the second leading cause of blindness worldwide. Ocular hypertension (OH) is the term used to describe the presence of raised intraocular pressure (the most important risk factor for the development of glaucoma) in the absence of demonstrable glaucomatous optic neuropathy.
The management of glaucoma and OH requires a holistic and rational approach, taking into account a number of factors. Treatment needs to be individualized depending on patient age, the severity and type of glaucoma, associated medical conditions, the condition of the ocular surface, tolerability of topical medication, and patient wishes. An understanding of the mechanism of glaucoma and its etiology in a particular patient is crucial for the initiation of appropriate treatment.
This review article summarizes the existing medical management of glaucoma and OH, including pharmacology, mode of action, and safety profile for each major group of medication, and reviews current advances and future developments in treatment for glaucoma, including experimental medications, together with a summary of their modes of action, pharmacology, and safety profiles. It is hoped that readers will become more aware of the evolution of the next generation glaucoma and OH medications.
RIS citation (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)
BibTex citation (BIBDESK, LATEX)
I would like to express my gratitude to all the staff of LA's journals. I published twice and I will certainly continue with LA's journals in the future. Thank you for providing a sustainable publishing environment for us.
All authors are surveyed after their articles are published. Authors are asked to rate their experience in a variety of areas, and their responses help us to monitor our performance. Presented here are their responses in some key areas. No 'poor' or 'very poor' responses were received; these are represented in the 'other' category.See Our Results
Copyright © 2013 Libertas Academica Ltd (except open access articles and accompanying metadata and supplementary files.)
Facebook Google+ Twitter
Pinterest Tumblr YouTube